Dogwood Therapeutics to Present at Maxim Growth Summit Amid Key…

Event summary

Dogwood Therapeutics (Nasdaq: DWTX) will participate in the 2026 Maxim Growth Summit from October 12-14, 2026, in New York.
CEO Greg Duncan will meet with institutional investors and engage with senior Maxim research analysts.
Dogwood recently completed enrollment in its Halneuron® Phase 2b Trial, with topline data expected in November 2026.
Halneuron® is a non-opioid, NaV 1.7 analgesic with FDA fast track designation for treating chemotherapy-induced neuropathic pain (CINP).
SP16 IV, another pipeline candidate, is funded by the National Cancer Institute for a Phase 1b CIPN trial.

The big picture

Dogwood Therapeutics' participation in the Maxim Growth Summit comes at a critical juncture, with the impending readout of its Halneuron® Phase 2b trial. The company is positioning itself as a leader in non-opioid pain management, a growing sector driven by the opioid crisis and increasing demand for safer alternatives. The involvement of its largest shareholder, CK Life Sciences, adds strategic depth, while the National Cancer Institute's funding for SP16 IV underscores the clinical and commercial potential of its pipeline.

What we're watching

Clinical Data Impact: How the November 2026 Halneuron® Phase 2b trial results will influence investor sentiment and potential partnerships.
Investor Sentiment: Whether Dogwood can leverage the Maxim Growth Summit to attract new institutional investors amid a competitive biotech landscape.
Regulatory Pathway: The pace at which Dogwood advances Halneuron® through FDA approvals, given its fast track designation.